The North America Body Fluid Collection And Diagnostics Market would witness market growth of 6.5% CAGR during the forecast period (2022-2028).
The body fluid of humans contains saliva, blood, excreta, cerebrospinal fluid, and fluids of tissues are considered inviting sources for clinical biomarkers, specifically in chronic diseases which extremely impact human life. The examination of human body fluid allows for diagnosing diseases and tracking disease causes. It enables the forecast of prognosis and tracking of disease growth with affordability, less invasiveness, and quick sample collection & analysis.
Moreover, the structure of molecular expression level in the body fluid can assist in the revelation of modification of psychological position and cellular in the affected tissue. Thus, body fluid analysis is the most valuable process for the identification, tracking, management, and pre-response analysis of chronic disease and for reveling the possible pathogens of chronic disease.
By the body fluid analysis process, which is considered as a most favorable approaches in practice, one can identify chronic diseases like diabetes, hypertension, cancer, and glaucoma. This can help on building a more inclusive approach to the mechanism of pathology and physiology in chronic diseases, which could have a crucial role in offering early proof, more productive care, and greater patient results.
As per the Canadian Cancer Statistic by Canadian government, throughout the life period of a Canadian citizen, 43% of Canadian women and 45% of Canadian men have cancer. As the population of Canada will rise and become older, there will be increasing cases of new cancer patients. Cancer is the major cause of many deaths in Canada. Apart from the present improvement in cancer management and research, rising partiality care of cancer patients has been seen, especially with those who are socio-economically disadvantaged groups and under-served society.
The government of Canada is supporting those organizations who are helping out to fight against this disease. The Canadian government recently introduced a plan to offer $250 million dollars for five years to expand the work of these organizations that are fighting against cancer. With the rising number of cancer patients in Canada, there will be great investment opportunities for the major players in the regional market.
The US market dominated the North America Body Fluid Collection And Diagnostics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $12,613.9 million by 2028. The Canada market is poised to grow at a CAGR of 8.9% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 7.9% during (2022 - 2028).
Based on Product, the market is segmented into Kits & Consumables, Instruments and Tests/Services. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Fluorescence in situ hybridization (FISH) and Others. Based on Sample Type, the market is segmented into Blood, Urine, Saliva and Cerebrospinal Fluid. Based on Application, the market is segmented into Diagnostics & Monitoring, Therapeutic Decision Making and Prognostics & Screening. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Qiagen N.V., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Biocept, Inc., MDxHealth SA, and Guardant Health, Inc.
The body fluid of humans contains saliva, blood, excreta, cerebrospinal fluid, and fluids of tissues are considered inviting sources for clinical biomarkers, specifically in chronic diseases which extremely impact human life. The examination of human body fluid allows for diagnosing diseases and tracking disease causes. It enables the forecast of prognosis and tracking of disease growth with affordability, less invasiveness, and quick sample collection & analysis.
Moreover, the structure of molecular expression level in the body fluid can assist in the revelation of modification of psychological position and cellular in the affected tissue. Thus, body fluid analysis is the most valuable process for the identification, tracking, management, and pre-response analysis of chronic disease and for reveling the possible pathogens of chronic disease.
By the body fluid analysis process, which is considered as a most favorable approaches in practice, one can identify chronic diseases like diabetes, hypertension, cancer, and glaucoma. This can help on building a more inclusive approach to the mechanism of pathology and physiology in chronic diseases, which could have a crucial role in offering early proof, more productive care, and greater patient results.
As per the Canadian Cancer Statistic by Canadian government, throughout the life period of a Canadian citizen, 43% of Canadian women and 45% of Canadian men have cancer. As the population of Canada will rise and become older, there will be increasing cases of new cancer patients. Cancer is the major cause of many deaths in Canada. Apart from the present improvement in cancer management and research, rising partiality care of cancer patients has been seen, especially with those who are socio-economically disadvantaged groups and under-served society.
The government of Canada is supporting those organizations who are helping out to fight against this disease. The Canadian government recently introduced a plan to offer $250 million dollars for five years to expand the work of these organizations that are fighting against cancer. With the rising number of cancer patients in Canada, there will be great investment opportunities for the major players in the regional market.
The US market dominated the North America Body Fluid Collection And Diagnostics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $12,613.9 million by 2028. The Canada market is poised to grow at a CAGR of 8.9% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 7.9% during (2022 - 2028).
Based on Product, the market is segmented into Kits & Consumables, Instruments and Tests/Services. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Fluorescence in situ hybridization (FISH) and Others. Based on Sample Type, the market is segmented into Blood, Urine, Saliva and Cerebrospinal Fluid. Based on Application, the market is segmented into Diagnostics & Monitoring, Therapeutic Decision Making and Prognostics & Screening. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Qiagen N.V., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Biocept, Inc., MDxHealth SA, and Guardant Health, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Kits & Consumables
- Instruments
- Tests/Services
By Technology
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
- Fluorescence in situ hybridization (FISH)
- Others
By Sample Type
- Blood
- Urine
- Saliva
- Cerebrospinal Fluid
By Application
- Diagnostics & Monitoring
- Therapeutic Decision Making
- Prognostics & Screening
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc
- Bio-Rad Laboratories, Inc
- Illumina, Inc
- Qiagen N.V
- Johnson & Johnson
- F.Hoffmann-La Roche Ltd
- Laboratory Corporation of America Holdings
- Biocept, Inc
- MDxHealth SA
- Guardant Health, Inc
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Body Fluid Collection And Diagnostics Market, by Product
1.4.2 North America Body Fluid Collection And Diagnostics Market, by Technology
1.4.3 North America Body Fluid Collection And Diagnostics Market, by Sample Type
1.4.4 North America Body Fluid Collection And Diagnostics Market, by Application
1.4.5 North America Body Fluid Collection And Diagnostics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2021, Jan - 2022, Sep) Leading Players
Chapter 4. North America Body Fluid Collection And Diagnostics Market by Product
4.1 North America Kits & Consumables Market by Country
4.2 North America Instruments Market by Country
4.3 North America Tests/Services Market by Country
Chapter 5. North America Body Fluid Collection And Diagnostics Market by Technology
5.1 North America Polymerase Chain Reaction (PCR) Market by Country
5.2 North America Next Generation Sequencing (NGS) Market by Country
5.3 North America Fluorescence in situ hybridization (FISH) Market by Country
5.4 North America Others Market by Country
Chapter 6. North America Body Fluid Collection And Diagnostics Market by Sample Type
6.1 North America Blood Market by Country
6.2 North America Urine Market by Country
6.3 North America Saliva Market by Country
6.4 North America Cerebrospinal Fluid Market by Country
Chapter 7. North America Body Fluid Collection And Diagnostics Market by Application
7.1 North America Diagnostics & Monitoring Market by Country
7.2 North America Therapeutic Decision Making Market by Country
7.3 North America Prognostics & Screening Market by Country
Chapter 8. North America Body Fluid Collection And Diagnostics Market by Country
8.1 US Body Fluid Collection And Diagnostics Market
8.1.1 US Body Fluid Collection And Diagnostics Market by Product
8.1.2 US Body Fluid Collection And Diagnostics Market by Technology
8.1.3 US Body Fluid Collection And Diagnostics Market by Sample Type
8.1.4 US Body Fluid Collection And Diagnostics Market by Application
8.2 Canada Body Fluid Collection And Diagnostics Market
8.2.1 Canada Body Fluid Collection And Diagnostics Market by Product
8.2.2 Canada Body Fluid Collection And Diagnostics Market by Technology
8.2.3 Canada Body Fluid Collection And Diagnostics Market by Sample Type
8.2.4 Canada Body Fluid Collection And Diagnostics Market by Application
8.3 Mexico Body Fluid Collection And Diagnostics Market
8.3.1 Mexico Body Fluid Collection And Diagnostics Market by Product
8.3.2 Mexico Body Fluid Collection And Diagnostics Market by Technology
8.3.3 Mexico Body Fluid Collection And Diagnostics Market by Sample Type
8.3.4 Mexico Body Fluid Collection And Diagnostics Market by Application
8.4 Rest of North America Body Fluid Collection And Diagnostics Market
8.4.1 Rest of North America Body Fluid Collection And Diagnostics Market by Product
8.4.2 Rest of North America Body Fluid Collection And Diagnostics Market by Technology
8.4.3 Rest of North America Body Fluid Collection And Diagnostics Market by Sample Type
8.4.4 Rest of North America Body Fluid Collection And Diagnostics Market by Application
Chapter 9. Company Profiles
9.1 Thermo Fisher Scientific, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.5.2 Product Launches and Product Expansions:
9.1.5.3 Acquisition and Mergers:
9.2 Guardant Health, Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.5.2 Product Launches and Product Expansions:
9.2.5.3 Acquisition and Mergers:
9.3 Illumina, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.5.2 Acquisition and Mergers:
9.4 Qiagen N.V.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Partnerships, Collaborations, and Agreements:
9.4.5.2 Acquisition and Mergers:
9.5 Bio-Rad Laboratories, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.5.5.2 Product Launches and Product Expansions:
9.6 F. Hoffmann-La Roche Ltd.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expense
9.6.5 Recent strategies and developments:
9.6.5.1 Product Launches and Product Expansions:
9.7 Laboratory Corporation of America Holdings
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental Analysis
9.7.4 Recent strategies and developments:
9.7.4.1 Partnerships, Collaborations, and Agreements:
9.8 Johnson & Johnson
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental &Regional Analysis
9.8.4 Research & Development Expenses
9.9 Biocept, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Partnerships, Collaborations, and Agreements:
9.9.4.2 Product Launches and Product Expansions:
9.10. MDxHealth SA
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Regional Analysis
9.10.4 Research & Development Expenses
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Illumina, Inc.
- Qiagen N.V.
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Laboratory Corporation of America Holdings
- Biocept, Inc.
- MDxHealth SA
- Guardant Health, Inc.
Methodology
LOADING...
